ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
272,402
252,002
179,804
130,956
24,951
Cost of Revenue
4,490
4,212
2,519
1,371
0
Gross Profit
267,912
247,790
177,285
129,585
24,951
Operating Expense
579,839
560,217
462,775
465,197
427,489
Operating Income
-311,927
-312,427
-285,490
-335,612
-402,538
Net Non Operating Interest Income Expense
-45,082
-41,144
-30,523
-29,271
-14,196
Other Income Expense
9,615
8,890
6,771
4,516
3,904
Pretax Income
-347,394
-344,681
-309,242
-360,367
-412,830
Net Income Common Stockholders
-347,394
-344,681
-309,242
-360,367
-412,830
Diluted NI Available to Com Stockholders
-347,394
-344,681
-309,242
-360,367
-412,830
Basic EPS
-
-0.0109
-0.0109
-0.0144
-0.0167
Diluted EPS
-
-0.0109
-0.0109
-0.0144
-0.0167
Basic Average Shares
-
31,654
28,464
25,054
24,663
Diluted Average Shares
-
31,654
28,464
25,054
24,663
Total Operating Income as Reported
-311,927
-312,427
-285,490
-335,612
-402,538
Total Expenses
584,329
564,429
465,294
466,568
427,489
Net Income from Continuing & Discontinued Operation
-347,394
-344,681
-309,242
-360,367
-412,830
Normalized Income
-347,394
-344,681
-309,242
-360,367
-412,830
Interest Expense
45,082
41,144
30,523
29,271
14,196
Net Interest Income
-45,082
-41,144
-30,523
-29,271
-14,196
EBIT
-302,312
-303,537
-278,719
-331,096
-398,634
EBITDA
-298,881
-
-
-
-
Reconciled Cost of Revenue
4,490
4,212
2,519
1,371
0
Reconciled Depreciation
3,431
3,663
4,582
4,601
3,831
Net Income from Continuing Operation Net Minority Interest
-347,394
-344,681
-309,242
-360,367
-412,830
Normalized EBITDA
-298,881
-299,874
-274,137
-326,495
-394,803
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0